Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$40.59 USD
+0.35 (0.87%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $40.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 32% (80 out of 251)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.36 | 9.99 |
Current Quarter Estimate | -0.63 | 3.27 | 61.00 |
Year Ago Quarter Estimate | -0.58 | -4.89 | 54.84 |
Next Quarter Estimate | -0.07 | 4.49 | 63.00 |
Next Year Estimate | -1.25 | 25.31 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 251.08 | 17.60 | 15.67 |
Next Year | -159.52 | 9.50 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | NA | 21.60 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 15.36 | -8.79 |
Price/Book (MRQ) | 4.36 | 1.91 |
Price/Cash Flow (MRFY) | NA | 15.24 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | -87.29% |
Return on Equity (TTM) | 39.06% | -47.30% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.